抗体及抗体相关治疗药物的诊疗一体化应用
本文综述了抗体及抗体相关治疗药物在肿瘤诊疗一体化中的应用,利用SPECT和PET等分子影像技术无创评估放射性标记抗体的全身分布、靶点表达、肿瘤摄取、饱和情况及异质性。作者识别出24种在患者中用于诊疗一体化目的的PET放射性核素标记抗体或抗体相关治疗药物,并指出该方法要整合进标准诊疗需进一步规范相关操作流程。
要点
- 放射性标记的单克隆抗体及抗体相关治疗药物可用于肿瘤诊疗一体化。
- SPECT和PET可无创显示放射性标记抗体的全身分布及肿瘤靶点表达与异质性。
- 作者识别出24种在患者中用于诊疗一体化目的的PET放射性核素标记抗体或抗体相关治疗药物。
核心结论
- 抗体及抗体相关治疗药物的诊疗一体化在肿瘤学中具有研究价值,但需进一步规范相关操作流程才能整合进标准诊疗。
研究设计与样本
- 综述,汇总了临床前和临床肿瘤学中单克隆抗体及抗体相关诊疗一体化的研究进展。
主要发现
- 作者识别出24种在患者中用于诊疗一体化目的的PET放射性核素标记抗体或抗体相关治疗药物。
- 分子抗体影像可潜在阐明药物靶点表达、肿瘤内示踪剂摄取、肿瘤饱和及这些参数在肿瘤内的异质性。
- 选择诊疗一体化用放射性核素通常从匹配单克隆抗体或抗体相关治疗药物的血清半衰期与放射性核素的物理半衰期开始。
- PET显像比SPECT技术能提供更好的定量。
临床怎么用
- 原文未据此给出推荐。
局限性
- 该方法要整合进标准诊疗,需进一步规范相关操作流程。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In theranostics, radiolabeled compounds are used to determine a treatment strategy by combining therapeutics and diagnostics in the same agent. Monoclonal antibodies (mAbs) and antibody-related therapeutics represent a rapidly expanding group of cancer medicines. Theranostic approaches using these drugs in oncology are particularly interesting because antibodies are designed against specific targets on the tumor cell membrane and immune cells as well as targets in the tumor microenvironment. In addition, these drugs are relatively easy to radiolabel. Noninvasive molecular imaging techniques, such as SPECT and PET, provide information on the whole-body distribution of radiolabeled mAbs and antibody-related therapeutics. Molecular antibody imaging can potentially elucidate drug target expression, tracer uptake in the tumor, tumor saturation, and heterogeneity for these parameters within the tumor. These data can support drug development and may aid in patient stratification and monitoring of the treatment response. Selecting a radionuclide for theranostic purposes generally starts by matching the serum half-life of the mAb or antibody-related therapeutic and the physical half-life of the radionuclide. Furthermore, PET imaging allows better quantification than the SPECT technique. This information has increased interest in theranostics using PET radionuclides with a relatively long physical half-life, such as 89Zr. In this review, we provide an overview of ongoing research on mAbs and antibody-related theranostics in preclinical and clinical oncologic settings. We identified 24 antibodies or antibody-related therapeutics labeled with PET radionuclides for theranostic purposes in patients. For this approach to become integrated in standard care, further standardization with respect to the procedures involved is required.
引用
- Moek KL, Giesen D, Kok IC, et al. Theranostics Using Antibodies and Antibody-Related Therapeutics. J Nucl Med. 2017. PMID: 28864618. doi:10.2967/jnumed.116.186940
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。